Leveraging the Findings From First in-Human GSI-plus-BCMA Clinical Trial to Understand Mechanisms of Resistance & Optimize Efficacy

Time: 11:30 am
day: Day One

Details:

  • Exploring why mechanisms of resistance to BCMA targeted therapies require further elucidation
  • Understanding the impact of BCMA antigen density on response, needing to be further characterized
  • Discussing why the approach to sequencing BCMA targeting agents may require careful consideration

Speakers: